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Available online 27 May 2016Tumor heterogeneity is a crucial area of cancer researchwherein inter- and intra-tumor differences are investigated
to assess and monitor disease development and progression, especially in cancer. The proliferation of imaging and
linked genomic data has enabled us to evaluate tumor heterogeneity on multiple levels. In this work, we examine
magnetic resonance imaging (MRI) in patients with brain cancer to assess image-based tumor heterogeneity. Stan-
dard approaches to this problem use scalar summary measures (e.g., intensity-based histogram statistics) that do
not adequately capture the complete and ﬁner scale information in the voxel-level data. In this paper, we introduce
a novel technique, DEMARCATE (DEnsity-basedMAgnetic Resonance image Clustering for Assessing Tumor hEtero-
geneity) to explore the entire tumor heterogeneity density proﬁles (THDPs) obtained from the full tumor voxel
space. THDPs are smoothed representations of the probability density function of the tumor images. We develop
tools for analyzing such objects under the Fisher–Rao Riemannian framework that allows us to construct metrics
for THDP comparisons across patients, which can be used in conjunction with standard clustering approaches.
Our analyses of The Cancer Genome Atlas (TCGA) based Glioblastoma dataset reveal two signiﬁcant clusters of pa-
tients with marked differences in tumor morphology, genomic characteristics and prognostic clinical outcomes. In
addition, we see enrichment of image-based clusters with known molecular subtypes of glioblastoma multiforme,
which further validates our representation of tumor heterogeneity and subsequent clustering techniques.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Glioblastomamultiforme (GBM), also known as grade IV glioma, is a
morphologically heterogeneous disease that is the most common ma-
lignant brain tumor in adults (Holland, 2000). Despite recent advance-
ments in treatments and discoveries of molecular signatures which can
be effectively used in diagnosis, the prognosis for most patients with
GBM is extremely poor (Tutt, 2011;McNamara et al., 2013). In the Unit-
ed States alone, twelve thousand new cases are diagnosed every year
(www.abta.org/about-us/news/brain-tumor-statistics), among which
less than 10% of individuals survive 5 years after diagnosis (Tutt,
2011). Themedian survival time for patients diagnosedwith GBM is ap-
proximately 12months (McLendon et al., 2008). Biological features that
differentiate GBM from any other grade of brain tumor include there@mdanderson.org
pani).
. This is an open access article underpresence of dead cells (tissue necrosis) and an increased formation of
blood vessels near the tumor. Originating from a single cell, a tumor in-
variably exhibits heterogeneity in physiological and morphological fea-
tures as it progresses (Marusyk et al., 2012). This presents a
considerable challenge for predicting the impact of standard cancer
treatments such as chemotherapy and radiation therapy. Thus, explor-
ing tumor heterogeneity is critical in cancer research as inter- and
intra-tumor differences have stymied the systematic development of
targeted cancer therapies (Felipe De Sousa et al., 2013). However, stud-
ies that integrate molecular data (genomics), clinical data andmorpho-
logical tumor characteristics such as appearance, size, shape and
location, have the potential to provide improved and more systematic
quantiﬁcation of tumor heterogeneity (McLendon et al., 2008). Using
quantitative imaging features along with clinical features has been
shown to be effective in prediction of survival time, which is beneﬁcial
for treating patients with GBM (Mazurowski et al., 2013; Gevaert et al.,
2014). Colen et al. (Colen et al., 2014) showed that biomarker signa-
tures can be used to identify distinct GBM phenotypes associated withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ways. Thus, data integration can signiﬁcantly impact the development
of personalized therapeutic strategies for cancer, and for GBM in
particular.
Modern medical imaging techniques have been extensively used to
investigate tumor development in various contexts, including comput-
ed tomography (CT), positron emission tomography (PET) andmagnet-
ic resonance imaging (MRI) (Held et al., 1997; Tesa et al., 2008; Cheng et
al., 2013). In particular, MRI is frequently chosen over other imaging
modalities because it furnishes a wide range of image contrasts at
high resolution (Nyúl and Udupa, 1999). These images are primarily
used to exhibit and evaluate the location, growth and progression of tu-
mors, which serve as indicators for clinical decision making for patients
with GBM (McLendon et al., 2008). Recent technological advancements
have improved the resolution of MRI, allowing investigators to study
distributions of numerous tumor features like permeability in dynamic
contrast-enhanced MRI (DCE-MRI), vessel size index (VSI) and appar-
ent diffusion coefﬁcient (ADC) in diffusion MRI, etc. (Just, 2014).
The increasing availability of imaging data through digitalization has
spawned substantial computational efforts to quantify and extract fea-
tures from these routine diagnostic images – providing additional infor-
mation about the physiology of the tumors. Numerous physiological
features have been studied by using the (more detailed) voxel-level
data to visualize the progression (or regression) of tumors. However, in
almost all of these studies, some ‘summary’ parameters/metrics for the
entire regions of interest are evaluated. Baek et al. (Baek et al., 2012)
used skewness, kurtosis, histographic pattern, range and mode of the
MRI-based voxel intensity histograms. Song et al. (Song et al., 2013) uti-
lized the extreme percentiles (5th and 95th) as features for histogram
analysis to study GBM progression. Analogously, Just (Just, 2011) used
the25th and 75th percentiles in the context of gliomas.While thesemet-
rics have shown someutility in assessing tumor heterogeneity, they have
two major drawbacks. First, the choice of the number and location of
summary features (e.g., quantiles or percentiles) is somewhat subjective.
Second, and more importantly, these summary features fail to capture
the entire information in a histogram (or corresponding density) and
thus cannot detect small-scale and sensitive changes in the tumor due
to treatment effects (Just, 2014). Thus, using a few statistical features
to summarize the entire tumor image leads to signiﬁcant loss in statisti-
cal information, which potentially results in low prediction and correla-
tive power. Alternatively, one can exploit the entire histogram, or its
corresponding smoothed density proﬁle for a tumor, which contains
more detailed and reﬁned information about the voxel-level tumor char-
acteristics. By utilizing the entire density obtained from various medical
imaging modalities, more effective tools for assessing and analyzing
tumor heterogeneity can be developed, which leads to improved
methods to detect associations with clinical and genomic data.
To address these limitations and challenges, we have developed a
novel method for the statistical analysis of tumor heterogeneity: DEMAR-
CATE (DEnsity-basedMAgnetic Resonance image Clustering for Assessing
Tumor hEterogeneity). For each patient, we generate a density proﬁle of
voxel intensities that correspond to the segmented tumor region, and
use the space of probability density functions (PDFs) for building an ap-
propriate framework for metric-based clustering. In particular, we utilize
the geometry of this space for the purpose of comparing and clustering
patients based on these density proﬁles. To achieve this, we utilize the
Fisher–Rao Riemannian framework and construct ametric that quantiﬁes
the similarity (or dissimilarity) between the densities, which can then be
used in conjunctionwith standard clustering approaches. Themain inno-
vation of this approach is the use of the entire distribution of tumor inten-
sities as a representation of tumor heterogeneity, which is in contrast to
existing methods based on histogram summaries. Fig. 1 shows the sche-
matic analysis pipeline for DEMARCATE. Applying our methodology to
The Cancer Genome Atlas (TCGA) dataset for GBM, our analyses revealed
signiﬁcant patient clusters that correspond to different anatomical fea-
tures of the tumor, which suggested varying levels of diseaseaggressiveness. We validated our established cluster memberships to
known molecular subtypes, genomic signatures and prognostic clinical
outcomes using imaging biomarkers, which revealed new ﬁndings and
conﬁrmed several previous ﬁndings.
The rest of this paper is organized as follows. In Section 2,weprovide a
detailed description of the data used in this study. Section 3 focuses on the
statistical framework for DEMARCATE by analyzing tumor heterogeneity
under the Fisher–Rao Riemannian-geometric framework. In Section 4, we
describe the experimental results. In particular, we study the association
between tumor heterogeneity, patient survival, clinical covariates, and
the subtypes and genomic signatures of the tumors. We close with a
brief discussion and some directions for future work in Section 5.
2. GBM dataset
We collated radiologic images along with linked genomic and
clinical data from 64 patient samples for which the patients
consented under TCGA protocols (cancergenome.nih.gov). The im-
aging data consist of a series of pre-surgical T1-weighted post con-
trast and T2-weighted ﬂuid-attenuated inversion recovery (FLAIR)
magnetic resonance (MR) sequences from The Cancer Imaging Archive
(www.cancerimagingarchive.net). The acquisition sequences for both
imaging modalities are presented in Table B4 in the Appendix. The
dataset comprising survival times, clinical and genomic data for these
patients was obtained from cBioPortal (www.cbioportal.org).
2.1. Image pre-processing
The pre-surgical MR sequences (T1-weighted post contrast and T2-
weighted FLAIR) were processed before extracting the density proﬁles
of tumor intensities, whichwere then used to derive appropriate repre-
sentations of tumor heterogeneity. The image pre-processing steps are
as follows:
• Registration of T2-weighted FLAIRMR image to T1-weighted post con-
trast image;
• Inhomogeneity correction on the registered T2-weighted FLAIR and
original T1-weighted post contrast images: Registration and inhomo-
geneity correction were performed using Medical Image Processing
and Visualization software (mipav.cit.nih.gov), an open-source medi-
cal image processing program developed at the National Institutes of
Health. Inhomogeneity correction, also known as nonparametric,
nonuniform intensity normalization (N3) correction, was performed
to remove the shading artifacts in MRI scans;
• Semi-automated 3D/volumetric segmentation of tumors: Tumors were
segmented semi-automatically in 3D using the Medical Image Interac-
tion Toolkit MITK3M3 Image Analysis (v 1.1.0) (mitk.org/wiki/MIT),
which has been validated as a method to segment tumors in various
organ systems. The segmentation tools were used by the clinician to
contour the relevant area on multiple slices. These contours were then
interpolated to obtain the 3D volumetric tumor mask. The segmented
region corresponds to the contrast enhancing tumor on the T1-weight-
ed post contrast image. On the T2-weighted FLAIR image, the segment-
ed region corresponds to the solid tumor as well as regions of
inﬁltrating tumor and edema that are delineated by increased intensity.
Images and their 3D tumormaskswere subsequently resliced for isotro-
pic pixel resolution using the NIFTI toolbox in MATLAB. From these
resliced images, the slicewith the largest tumor area in the T1-weighted
post contrast image and the corresponding slice in the T2-weighted
FLAIR image were selected as the regions of interest (ROI) for analysis.
2.2. Clinical and genomic data/annotation
The imaging dataset is a subset of a larger patient dataset that con-
tains information on the linked clinical and genomic variables. For
Fig. 1. Brief outline of DEMARCATE.
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graphic variables that correspond to the clinical covariates in this
dataset are presented in Table 1. Recent investigations have identiﬁed
four subtypes of GBM: classical, mesenchymal, neural and proneural,
each of which is characterized by different molecular alterations
(Verhaak et al., 2010). Note that a GBM tumor can be classiﬁed as simul-
taneously belonging to two subtypes. We also curated the information
about these GBM subtypes (see Table B2 in the Appendix) and some
well-characterized driver genes (see Table B3 in the Appendix) that
are considered signiﬁcant in GBM (Frattini et al., 2013): DDIT3, EGFR,
KIT, MDM4, PDGFRA, PIK3CA and PTEN. Biologically, a gene is known
as a driver gene when it has a mutation along with DNA-level changes
(ampliﬁcations or deletions).
3. DEMARCATE statistical framework
In this section,we provide details of the statistical framework for DE-
MARCATE. As introduced in Section 1, our analytic pipeline consists of
three sequential components: (1) Extraction of the tumor voxel intensi-
ties from MR images to construct the PDFs – referred to as tumor het-
erogeneity density proﬁles (THDPs) – that serve as data objects for
this study (Section 3.1), (2) Transformation of the THDPs, which allows
for the comparison and modeling of such data objects using a compre-
hensive Riemannian–geometric framework in the statistical analysis
(Section 3.2), (3) Clustering of the subjects based on the geometry of
the space of THDPs using the Fisher–Rao Riemannian metric (Section
3.3). We also provide methods for visualizing the clusters, as well as
cluster validation (Section 3.4). Although the methods discussed in
the following sections are motivated by and described in the context
of the speciﬁcMRI-basedGBMstudy, they can be applied to any imaging
modality that generates voxel-level intensity data structures.
3.1. Extraction of tumor heterogeneity density proﬁles (THDPs) from MRI
data
In the ﬁrst step of DEMARCATE, we extract the image intensity
values associated with the segmented tumors. This process is schemat-
ically depicted in Fig. 2 for a T1-weighted post contrast MR image of a
typical patient. For all the patients, a similar (analogous) procedure is
used for the T2-weighted FLAIR MR image. We begin with a 2D slice
of an MR image and a binary mask delineating the tumor (left) as de-
scribed in Section 2.1. By fusing these two sources of information, we
are able to extract the image intensity values that correspond to the
tumor only. A histogram of the intensity values that correspond to the
extracted tumor region is shown in the third panel of Fig. 2. This is sub-
sequently used to generate a THDPwithout assuming a speciﬁc form for
the underlying distribution of the intensity values, i.e., a nonparametricTable 1
Patient demographics for the GBM dataset. Numbers in parentheses represent percent-
ages. Patient age and survival time are represented by the mean ± standard deviation.
Characteristic
Sex
Male (%) 43 (67.19)
Female (%) 21 (32.81)
Age (in years) 56.53 ± 15.40
Survival (in months) 17.53 ± 14.15representation. We use the kernel density estimation technique
(Rosenblatt, 1956) to determine the density proﬁle directly from the
MR image for a given patient. We choose the standard Gaussian kernel
as the smoothing function, with the default bandwidth that is theoreti-
cally optimal for the Gaussian kernel (Silverman, 1986). The right panel
of Fig. 2 displays the kernel density estimate based on the tumor inten-
sity value histogram. Note that after the density estimate is computed,
we normalize its domain to [0,1]. This is done to remove the relative
variability in MRI pixel intensities across patients, which is a common
phenomenon in MRI data (Nyúl and Udupa, 1999). We repeat this pro-
cedure for both modalities and across all 64 patients. As a result, our
data objects for the downstream analyses consist of these T1-weighted
post contrast and T2-weighted FLAIR THDPs. The DEMARCATE frame-
work is readily adapted to bivariate THDPs estimated using both (or
more) imaging modalities (we use the intersection of the T1-weighted
post contrast and T2-weighted FLAIR binary tumor masks to extract
the respective image intensity values). While the description of the
framework focuses on the univariate case for simplicity, we present re-
sults of univariate and bivariate THDP analysis in Section 4. Since the
THDP data objects are actually bonaﬁde PDFs (i.e., they integrate to 1),
we require tools for statistical analysis on the space of PDFs, which we
discuss in the next section.
3.2. Space of probability density functions and the Fisher–Rao Riemannian
metric
In the following steps of DEMARCATE, we exploit the differential ge-
ometry of the nonlinear space on which the THDPs lie. We begin with
the deﬁnition of the nonlinear representation space, which we restrict
to the case of univariate densities on [0,1]. Let P denote the Banach
manifold of THDPs: P ¼ f f : ½0;1→ℝ≥0j∫10 f ðtÞdt ¼ 1g. We note that P
has a boundary, which contains all THDPs for which normalized pixel
values become 0 anywhere on the domain. Next, we consider a vector
space that contains the set of tangent vectors at a point inP. Intuitively,
this space contains all possible perturbations of a THDP f. For any point
f∈P, the tangent space at that point is deﬁned as T f ðPÞ ¼ fδf : ½0;1→ℝ
j∫10δf ðtÞ f ðtÞdt ¼ 0g. This tangent space will be used to deﬁne a suitable
metric between two THDPs on the manifold.
Since our ﬁnal objective is to cluster the patients using their THDPs,
we need an appropriatemetric to compute distances onP. One intrinsic
Riemannian metric that can be used for this purpose is the Fisher–Rao
(FR) Riemannian metric. For any two tangent vectors δ f 1; δ f 2∈T f ðPÞ,
the nonparametric version of the FR metric is deﬁned by the following
inner-product (Rao, 1945; Kass and Vos, 2011):
δ f 1; δ f 2h ih i ¼
Z 1
0
δ f 1 tð Þδ f 2 tð Þ
1
f tð Þ dt: ð1Þ
The FR metric has been used in various applications in computer vi-
sion (Srivastava et al., 2007). Additionally,metrics related to the FRmet-
ric have been widely used for statistical shape analysis (Peter and
Rangarajan, 2006; Srivastava et al., 2011; Kurtek et al., 2012). A crucial
property of this metric, making it very appealing for statistical analysis,
is that it is invariant to re-parameterizations (smooth one-to-one trans-
formations of the domain) of PDFs (Cencov, 2000). Since the FR metric
changes from point to point on the space of THDPs, the computation
Fig. 2. Extraction of a THDP. Leftmost two panels: T1-weighted post contrast MR image of a tumor (top) and the corresponding tumormask (bottom). Second panel:Mask overlaid on the
tumor. Third panel: Histogram of pixel intensities corresponding to the tumor. Right: Estimated probability density function representation of tumor heterogeneity (THDP).
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tances between these THDPs is very cumbersome, requiring numerical
methods to approximate the metric on P. Thus, instead of working on
the BanachmanifoldP directly, it is useful to select a suitable represen-
tation of the space for which the calculations become much easier. In
particular, we want to use a transformation on the THDPs such that
the nonlinear space changes to a simpler space and computation of
the FR metric becomes more convenient.
A convenient choice of representation for THDPs, which helps us
overcome the aforementioned computational issue, is its square root
representation introduced by Bhattacharyya (Bhattacharyya, 1943).
We deﬁne a continuousmappingϕ : P→Ψ, where the square root trans-
form (SRT) of a THDP f is given by ϕð f Þ ¼ ψ ¼ þ
ﬃﬃﬃ
f
p
. The inverse map-
ping is simply ϕ−1(ψ)= f=ψ2 (Kurtek and Bharath, 2015). The space
of SRT representations of THDPs is given by Ψ ¼ fψ : ½0;1→ℝ≥0j
∫10ψ
2ðtÞdt ¼ 1g and represents the positive orthant of the unit Hilbert
sphere (Lang, 2012). Furthermore, let Tψ(Ψ)={δψ |bδψ ,ψN=0} denote
the tangent space at ψ (for elements not lying on the boundary). With
the choice of SRT representation, for any two vectors δψ1 ,δψ2∈Tψ(Ψ),
the FR metric deﬁned in Eq. (1) becomes the standard L2 Riemannian
metric:
δψ1; δψ2h i ¼
Z 1
0
δψ1 tð Þδψ2 tð Þdt: ð2Þ
To summarize, the SRT representation of PDFs provides two impor-
tant simpliﬁcations: (1) the nonlinear space of THDPs becomes the pos-
itive orthant of the unit Hilbert sphere, and (2) the complicated FR
metric reduces to the standardL2metric. Because theL2 Riemannian ge-
ometry of the unit sphere is well known, quantities of interest such as
geodesic paths and distances between THDPs can be calculated analyt-
ically, and thus, in a computationally efﬁcient manner.
3.3. Statistical analysis of the transformed THDPs
We begin with the deﬁnition of the FR distance using the geometry
of ψ, i.e., the space of the square root transformed THDPs. This metric
will be used to cluster patients with GBM based on their THDPs. The
geodesic distance between two THDPs f1 , f2∈P, represented by their
SRTs ψ1 , ψ2∈Ψ, is deﬁned as the shortest arc connecting them onΨ:
cos−1(ψ1,ψ2)=θ, where the inner product is given by Eq. (2). Wedenote this distance as d(f1, f2)FR. This is also the standard L2 distance
between ψ1 and ψ2 on Ψ, denoted by dðψ1;ψ2ÞL2 or dðϕð f 1Þ;ϕð f 2ÞÞL2 .
Since we are restricted to the positive orthant of the unit sphere, the
geodesic distance θ between two THDPs is bounded above by π/2. Fig.
3 provides a description of these ideas. We start with two THDPs, f1
and f2, which are points on the Banach manifold P. The FR distance be-
tween f1 and f2 is given by the length of the shortest geodesic path be-
tween them; unfortunately, this quantity is difﬁcult to compute. We
use the SRT mapping to simplify the geometry of P to Ψ, the positive
orthant of the Hilbert sphere, where the FR metric becomes the stan-
dard L2 metric. Now, the FR distance between f1 and f2 on P is simply
the shortest arc between their SRT representations ψ1 and ψ2 onΨ.
Theﬁnal step of DEMARCATE,which consists of groupingpatients on
the basis of their tumor heterogeneity proﬁles, uses k-means clustering
of THDPs. To proceed, we must specify two important tools from differ-
ential geometry required for implementing such an algorithm on this
space: the exponential and inverse-exponential maps. For ψ∈Ψ and
δψ∈Tψ(Ψ), the exponential map at ψ, exp:Tψ(Ψ)→Ψ is deﬁned as
expψ δψð Þ ¼ cos δψk kð Þψþ sin δψk kð Þ
δψ
δψk k : ð3Þ
Similarly for ψ1 , ψ2∈Ψ, the inverse-exponential map denoted by
expψ−1:Ψ→Tψ(Ψ) is given by
exp−1ψ1 ψ2ð Þ ¼
θ
sin θð Þ ψ2− cos θð Þψ1ð Þ; ð4Þ
where θ=cos−1(〈ψ1,ψ2〉). With the help of these two expressions, we
can map points from the representation space Ψ that contain all the
SRTs of THDPs to the tangent space ofΨ (Tψ(Ψ)), and vice versa.
We are now in a position to exploit the geometry of Ψ to deﬁne an
average THDP. The average (or mean) THDP is a representative density
proﬁle of the tumor intensity values across multiple patients, which al-
lows us to efﬁciently summarize and visualize different GBM groups
using their THDPs. A generalized version of the mean on a metric
space that can be used to compute the average THDP is the Karcher
mean (Karcher, 1977). The sample KarchermeanψonΨ is theminimiz-
er of the Karcher variance ρðψÞ ¼∑
n
i¼1
dðψ;ψiÞ
2
L2 , i.e., ψ ¼ argminψ∈Ψ
∑ni¼1dðψ;ψiÞ2L2 . An algorithm for calculating this mean is presented in
Fig. 3. Graphical representation of the square root transform (SRT) from P to the positive orthant of the unit Hilbert sphereΨ, where f1, f2 represent two THDPs and θ is the FR geodesic
distance between them.
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mean is an intrinsic average that is computed directly onΨ (or equiva-
lently P). We are thus equipped with a mean that is an actual THDP
(Karcher mean) and a distance function (FR metric) that we can effec-
tively use to specify a clustering algorithm directly on the space of
THDPs.
3.4. Cluster analysis
There are many possible choices of clustering methods that can be
used in the current problem. Speciﬁcally, we want to utilize an intrinsic
version of the k-means clustering technique onΨ. This approach parti-
tions the space by minimizing the within-cluster sum of squared dis-
tances (using the FR metric) to the assigned cluster center. The k-
means clustering algorithm for THDPs is provided in the Appendix
(see Algorithm A2). This algorithm has two main constraints:
(i) The number of clusters kmust be speciﬁed beforehand;
(ii) The solution depends on the initialization of the cluster means.
We address these two issues in the current problem as follows. The
ﬁrst constraint is application dependent and context-speciﬁc –
governed by both sample size and interpretability of the clusters. In
our setting, we ﬁx the number of clusters at k=2. This is natural since
our primary objective is to ﬁnd two groups of GBM patients with a
high difference in survival time (long versus short survival times). Fur-
ther, the tumor driver gene covariates are binary, which makes it natu-
ral to study whether the two clusters effectively capture the presence
versus absence of driver gene mutations. In other contexts, different
cluster conﬁgurations could be run in parallel as well. In the next sec-
tion, we address the second issue listed above.
3.4.1. Cluster initialization
There are various choices for initializing the two clustermeans in the
k-means clustering algorithm. Since we have the ability to quickly com-
pute the pairwise distances for all THDPs using the FRmetric, we look at
clustering methods that can be implemented using a distance matrix,
i.e., hierarchical clustering with complete linkage, hierarchical cluster-
ing with average linkage, and partitioning around medoids (PAM)
(Theodoridis and Koutroumbas, 2006). For each of these methods, we
calculate the clustermembership for each patient. Accordingly, we eval-
uate the Karcher means and Karcher variances for each cluster.
Let ρ1ðψ1Þ and ρ2ðψ2Þ be the sample Karcher variances (Section 3.3)
for clusters 1 and 2 of sizes n1 and n2, respectively. To initialize the k-
means clustering algorithm, we select the method that minimizes the
pooled Karcher variance: n1ρ1ðψ1Þþn2ρ2ðψ2Þn1þn2 , i.e., the method that produces
the smallest weighted average of cluster-wise sample Karchervariances. It must be noted that the initialization of the cluster means
is data-dependent. There is no uniquemethod for initializing the cluster
means; rather, it can vary from dataset to dataset. Once we select the
‘optimal’ initialization technique,we can use it to specify the twounique
functions (see Algorithm A2 in the Appendix) to initialize the k-means
algorithm.
3.4.2. Cluster visualization
In standard settings, it is difﬁcult to intuitively visualize THDPs for
different imaging modalities, especially in higher dimensions. Thus,
we explore the variability in the THDPs using principal component anal-
ysis (PCA), which is an effective method for visualizing the primary
modes of variation in data. Note that this visualization is possible be-
cause of the FR-geometric framework. Since the tangent space is a vec-
tor space (Euclidean), PCA can be implemented, as in standard
problems.
Suppose there are nMR images leading to n THDPs. To suitably im-
plement PCA on the space generated by these THDPs, we perform the
following steps:
(i) Compute ψ1 ,… ,ψn using the SRT of the THDPs.
(ii) Compute ψ, the Karcher mean of ψ1 ,… ,ψn using Algorithm A1.
(iii) For i=1,… ,n, compute vi ¼ exp−1ψ ðψiÞ using the inverse-expo-
nential map.
(iv) Compute the sample covariance matrix. At the implementation
stage, THDPs are typically sampled using N points, resulting in
an N×N covariance matrix given by K ¼ 1n−1∑
n
i¼1
vivTi . In practice,
vi’s are N-dimensional vectors that represent the density values
at N points on its domain.
(v) Perform singular value decomposition (SVD) of K. Since K is sym-
metric, SVD of K is given by K=UΣUT.
Σ is a diagonal matrix containing the principal component variances or-
dered from largest to smallest. The columns of U represent the corre-
sponding principal modes of variation in the given data. The principal
components computed using these steps can also be used to visualize
the THDPs in a lower dimensional space.
3.4.3. Cluster validation
We provide a general Bayesian strategy for cluster validation –
wherein we investigate the association between cluster partitions and
external information (i.e., covariates) on the cluster-speciﬁc subjects.
To concretize the discussions, we describe this approach in the context
of our GBM MRI example, where we study association between the
computed clusters and various covariates that include information
about tumor subtypes and genomic mutation status of driver genes
(as described in Section 2.2).
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clusters will exhibit higher rates of enrichment for speciﬁc covariate
values. To estimate the enrichment, we use a Bayesianmodel-based ap-
proach under a beta-binomial samplingmodel.We beginwith a contin-
gency table that displays the frequency distribution of a particular
dichotomous covariate in each cluster. An illustration of such a contin-
gency table is given in Table 2. We want to compare the relative occur-
rence of a speciﬁc covariate across clusters. We recast the problem in
terms of a binomial probabilitymodel. Let θ1∈ [0,1] denote the true pro-
portion of A in cluster 1. Similarly, let θ2∈[0,1] denote the true propor-
tion of A′ in cluster 1. Accordingly, y11~Binomial(n1,θ1) and
y21~Binomial(n2,θ2). Consider a uniform prior (Uniform(0,1)) on the
true proportions θ1 and θ2, which is equivalent to a Beta(1,1) prior.
Since the Beta distribution is conjugate for the binomial, the posterior
distribution is of the same family as the prior. The resulting posterior
distributions for θ1 and θ2 are given by
πθ1 θ1jy11;n1ð Þ  Beta y11 þ 1;n1−y11 þ 1ð Þ
πθ2 θ2jy21;n2ð Þ  Beta y21 þ 1;n2−y21 þ 1ð Þ:
We generate a large numberm of samples from the two posteriors
πθ1 and πθ2, resulting in a set of pairs {(θ1
(1),θ2(1)), … , (θ1(m),θ2(m))}.
Then, we can approximate the true probability P(θ1Nθ2) using a
Monte Carlo estimate as follows: Pðθ1Nθ2Þ≈E ¼ 1m∑
m
i¼1IðθðiÞ1 NθðiÞ2 Þ ,
where I is the indicator function that equals 1 if θ1(i)Nθ2(i) , i=1,… ,m,
and 0 otherwise. The intuition behind this approach is as follows. If the
computed cluster 1 is not associated with the dichotomous covariate
of interest, the values of y11 and y21 should be similar, resulting in essen-
tially the same posteriors for θ1 and θ2. This in turn would result in a
Monte Carlo estimate of P(θ1Nθ2) close to 0.5, or no enrichment of that
covariate in cluster 1. On the other hand, if y11 and y21 are drastically dif-
ferent, this manifests itself in the posterior distribution, and the Monte
Carlo estimate of P(θ1Nθ2) would be either very close to 1 (if y11 is
much larger than y21), or 0 (if y11 is much smaller than y21). These two
scenarios constitute high enrichment of the covariate in one of the clus-
ters (cluster 1 if P(θ1Nθ2) is close to 1 and cluster 2 if P(θ1Nθ2) is close to
0).
We represent enrichment probabilities (EP) for each covariate (i.e.,
tumor subtype and mutation status of driver genes) in each cluster
using an enrichment matrix in which each row in the matrix corre-
sponds to the aforementioned covariates, and the columns contain en-
richment values for the appropriate cluster (ranging between 0 and
1). Thus, an individual cell represents the posterior probability of a mo-
lecular tumor subtype or driver gene being enriched in that speciﬁc
cluster. Graphically, this enrichment probability is represented by a
grayscale heatmap inwhich dark gray or black cells indicate greater en-
richment of a covariate in that cluster.
4. Application to GBMMRI data
In this section, we use DEMARCATE to study the MRI-based tumor
heterogeneities for each patient and for each imaging modality (T1-
weighted post contrast and T2-weighted FLAIR). We exploit the full
tumor voxel space and generate univariate and bivariate THDPs to
study tumor heterogeneity. We cluster the patients based on their re-
spective THDPs (Section 4.1) and then visualize the clusters on aTable 2
Contingency table showing frequency distribution of a categorical covariate in both clus-
ters for any image modality. A symbolizes the presence of a molecular tumor subtype or
a driver genemutation, whereas A′ represents the absence of such a subtype or mutation.
Cluster 1 Cluster 2 Total
A y11 y12 n1=y11+y12
A′ y21 y22 n2=y21+y22
Total y11+y21 y12+y22 n=n1+n2lower dimensional space (Section 4.2). In the following section
(Section 4.3), we relate the clusters to prognostic clinical outcomes.
We also compare the clustering performance of DEMARCATE to that of
popular scalar histogram summary measures such as skewness, kurto-
sis, percentiles, etc. (Section 4.4). Finally, we validate the clusters
using known linked clinical outcomes and radiogenomic covariates,
i.e., tumor subtypes and genomic signatures (Section 4.5).
4.1. Clustering results
For the TCGA dataset, we consider estimation of three different
THDPs based on the MRI modalities:
• Univariate THDP for T1-weighted post contrast,
• Univariate THDP for T2-weighted FLAIR,
• Bivariate THDP for joint analysis of T1-weighted post contrast and T2-
weighted FLAIR.
As discussed in Section 3.4, to implement the intrinsic k-means cluster-
ing algorithm, we need to select an appropriate cluster initialization
method.We choose themethod based on theminimumpooled Karcher
variance criterion. The pooled Karcher variances for the three initializa-
tion methods we considered are provided in the Appendix (see Table
B1). For all three cases, the PAMmethod produces the minimum value
for the pooled variance and is thus chosen for initializing the k-means
clustering algorithm.
The number of subjects for the two clusters computed using DE-
MARCATE are given below:
• For the T1-weighted post contrast MRImodality, cluster 1 contains 24
subjects and cluster 2 contains 40 subjects.
• For the T2-weighted FLAIR MRI modality, cluster 1 contains 30 sub-
jects and cluster 2 contains 34 subjects.
• For the bivariate modality, cluster 1 contains 19 subjects and cluster 2
contains 45 subjects.
The number of subjects in the T2-weighted FLAIR clusters are almost
comparable whereas the T1-weighted post contrast clusters are slightly
unbalanced; the clusters computed for the bivariate modality are also
unbalanced. The average THDPs for the T1-weighted post contrast clus-
ters are shown in the top left panel of Fig. 4; the average THDPs for the
T2-weighted FLAIR clusters are shown in the top right panel of Fig. 4. In
both cases, the cluster 1 THDP is displayed in blue, and the cluster 2
THDP is shown in red. The cluster-wise average THDPs for both modal-
ities are considerably different with respect to the mean and spread,
with the red THDP (cluster 2) always having much higher average
tumor intensity values. We note that the modes for THDPs in each clus-
ter are quite different. The cluster-wise average bivariate THDPs are
shown in the bottom panel of Fig. 4. The average THDP for cluster 1
has a much higher and tighter peak, as can be seen in the left panel,
than the average THDP for cluster 2 (right panel). Note that each bivar-
iate THDP is plotted on the same scale and thus can be compared visu-
ally. In each case, the average THDPs represent the entire set of features
for a cluster, which cannot be captured by the often-used histogram
summaries like skewness, kurtosis, mode and percentiles.
To aid visualization in the original voxel space, we plot a few exam-
ples of the actual tumor images in Fig. 5. We ﬁnd that typical patients in
each T1-weighted post contrast cluster display marked phenotypic
tumor differences. For patients in cluster 1, we observe an explicit
‘ring-like’ boundary of the tumor (panel (a)), which is characterized
by the sharp mode of the THDP, as shown in panel (b). THDPs in this
cluster are mostly unimodal, with a sharp peak representing pixel
values in the interior tumor region. In cluster 2, we note bimodal
THDPs, where the distribution of pixel intensity values in the corre-
sponding tumor regions is more heterogeneous. Also, the mode for
THDPs in cluster 2 shifts to the right as compared to cluster 1, which
Fig. 4. Top: Average cluster THDPs for T1-weighted post contrastMR images (left) and T2-weighted FLAIRMR images (right). Cluster 1 is depicted in blue and cluster 2 in red. Bottom: Average
bivariate THDPs for cluster 1 (left) and cluster 2 (right).
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mors in cluster 2. Thus, based on the T1-weighted post contrast imaging
modality, we ﬁnd two markedly distinct image-based clusters with dif-
ferences in tumor attributes. Similarly, cluster 2 is hyperintense based
on the T2-weighted FLAIR signal, which corresponds to edema and inﬁl-
trated tumor cells (Hawkins-Daarud et al., 2013; Zinn et al., 2011). We
emphasize that THDP cluster visualization is a difﬁcult task. In this sec-
tion, we have provided crude summaries of the clusters via average
THDPs and a few cluster representatives. In order to capture the com-
plex structure of clusters, it is better to study and visualize the cluster-
wise variability, which is better at capturing the inter- and intra-
tumor heterogeneity.Fig. 5. (a) T1-weighted post contrast MR images for three typical patients in cluster 1 (top) an4.2. Cluster visualization using PCA
Utilizing the algorithm for PCA discussed in Section 3.4.2, we display
the computed clusters (for the univariate case only) using a lower di-
mensional representation of the tangent space TψðΨÞ. We investigate
the cluster-wise principal directions of variation in each modality
using t
ﬃﬃﬃﬃﬃﬃ
Σii
p
Ui for t ranging from−2 to +2, with t=0 corresponding
to the mean. The value
ﬃﬃﬃﬃﬃﬃ
Σii
p
refers to the square root of the ith element
of the diagonal matrix Σ (variance of the ith principal component), and
Ui refers to the ith column of U (ith principal direction of variation). Fig.
6 shows the three principal directions of cluster-wise variability (i=d cluster 2 (bottom). (b) Corresponding THDPs for cluster 1 (top) and cluster 2 (bottom).
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modalities. For each imaging modality, the dominant (ﬁrst) direction
of variability shows signiﬁcant changes in the mode as we differ from
the mean, i.e., as we vary t. Such transformations reﬂect natural differ-
ences in relative proportions of the different tumor tissue compart-
ments. When examining the second and third principal directions of
variability, we notice more complex structure where THDPs change in
shape and the number of modes. This suggests that the computed clus-
ters capture both, simple THDP mode differences (shifts shown in the
ﬁrst direction) and ﬁner changes in shape and multimodality (the sec-
ond and third directions). As mentioned earlier, such complex cluster
structure is difﬁcult to capture using histogram summary statistics. A
display of the projection of the THDPs onto the two-dimensional princi-
pal subspace aswell as the dominant direction of variability in eachmo-
dality are provided in Fig. 9 in the Appendix.
4.3. Cluster association with linked prognostic clinical outcomes
Next, we relate the computed cluster membership from all the esti-
mated THDPs to their survival time and other clinical prognostic indica-
tors. We note a marked cluster difference between the distributions of
survival times. In particular, cluster 1 with the ring-like structures has
a higher mean and median survival time compared to cluster 2 (Fig.
7) for all three modalities.
The results for survival times are summarized in Table 3. These re-
sults are consistent with our ﬁnding that the mean of the average
THDP in cluster 1 is always lower than that in cluster 2, as can be clearly
seen from Fig. 4. This suggests that the heterogeneity of pixel intensities
captured through the density representation of a tumor may be related
to a patient's survival prognosis. The altered hyperintensity between the
clusters derived from T2-weighted FLAIR MR images suggests a clear
survival difference based on varying inﬁltrative characteristics of the
tumor. We emphasize that the mean (andmedian) survival differences
across the two clusters found using the THDPs are quite large (3–
7months), especially in the context of GBM – considering that the over-
all median survival in GBM is only around 12 months, as indicated in
Section 1.Fig. 6. First three principal directions (top to bottom) of cluster-wise variability (left to right)
mean; cyan =+1 sd; magenta =+2 sd.4.4. Performance of clustering algorithms based on standard summary
features
Table 4 provides statistics for the histogram summary features pro-
posed in Section 1. The left column lists the features considered for
histogram analysis in previous clinical studies. We do not use the bi-
variate THDP representation in this case since, to the best of our
knowledge, extracting statistical summary features from bivariate his-
tograms has not been previously considered in any GBM study. We
apply k-means clustering using the univariate features and note the
difference in mean and median survival times for each method. To im-
plement the clustering algorithm, we choose 100 different initializa-
tions to calculate the clusters. For each imaging modality, the
average difference in mean and median survival times, along with
their standard deviations are reported. We note that for both imaging
modalities, DEMARCATE generally performs better. We always obtain
a greater difference in mean survival time (Table 3) using DEMAR-
CATE, which validates our representsation of tumor heterogeneity
and geometry-based clustering.4.5. Cluster validation using radiogenomic associations
Certainmolecular and genomic signatures related to the growth and
progression of GBM provide useful information for the clinical manage-
ment of the disease. In a secondary analysis, we aim to validatewhether
the clusters are characterized by salient features based on tumor sub-
types (see Table B2 in the Appendix) and to verify the mutation status
of driver genes (see Table B3 in the Appendix). This helps us to biolog-
ically relate each cluster to the differently expressed driver genes. The
GBM genes that are used to validate our clustering technique are
genes targeted by somatic mutations and copy number variations
(Frattini et al., 2013). In primary GBM, EGFR ampliﬁcation is the most
frequently ampliﬁed and over expressed gene (30%–70%) (McNamara
et al., 2013). Similarly, a tumor suppressor gene, PTEN, is deleted in
50%–70% of cases and mutated in 14%–47% cases of primary GBM
(Simpson and Parsons, 2001). Thus, a study of these emergingin THDPs for each modality. Blue =−2 standard deviations (sd); green =−1 sd; red =
Fig. 7. Boxplots of cluster-wise survival times (inmonths) for the T1-weighted post contrast MRImodality (left), T2-weighted FLAIRMRImodality (center) and bivariatemodality (right).
Table 4
Comparison of various clustering methods based on histogram summary measures. The
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guide patient-speciﬁc therapies.
For each imagingmodality (including bivariate), enrichment for the
different covariates in each cluster is calculated using the methodology
described in Section 3.4.3. The enrichment plots (overlayedwith enrich-
ment probabilities) in Fig. 8 display results consistent with some of the
well-characterized genomic signatures in GBM. In each case, we found
associations between tumor subtypes and driver gene mutations that
are in concordance with prior studies and corroborate their ﬁndings.
Below, we present our ﬁndings and cite the relevant references where
these associations have been studied before. For the T1-weighted post
contrast MRI modality:
• Proneural subtype (EP=0.74) and PDGFRA (EP=0.87) are enriched
in the same cluster (cluster 1) (Verhaak et al., 2010);
• Mesenchymal subtype (EP=0.73) and PTEN (EP=0.54) are enriched
in the same cluster (cluster 2) (McNamara et al., 2013).
For the T2-weighted FLAIR MRI modality, we found the following
associations:
• Classical subtype (EP=0.85) and EGFR (EP=0.55) are enriched in the
same cluster (cluster 2) (Verhaak et al., 2010);
• Neural subtype (EP=0.90) and many of the driver genes including
DDIT3 (EP=0.73), EGFR (EP=0.55), KIT (EP=0.60), PDGFRA (EP=
0.58), PIK3CA (EP=0.98), PTEN (EP=0.73) are enriched in the
same (cluster 2). For the neural subtype, McNamara et al.
(McNamara et al., 2013) described mutations in many of the same
genes as the other three subgroups, which can be seen from our en-
richment plot.Table 3
Summary statistics for cluster-wise survival times (inmonths) for eachmodality. The sur-
vival time differences are highlighted in bold.
Mean Median
Cluster
1
Cluster
2
Difference Cluster
1
Cluster
2
Difference
T1-weighted
post contrast
22.06 14.81 7.25 17.00 12.95 4.05
T2-weighted
FLAIR
20.28 15.11 5.17 16.60 13.45 3.15
Bivariate 22.37 15.49 6.88 18.40 13.30 5.10Similarly, for the bivariate clusters based on joint analysis of T1-
weighted post contrast and T2-weighted FLAIR, we ﬁnd the following
associations:
• Proneural subtype (EP=0.73) and PDGFRA (EP=0.54) are enriched
in the same cluster (cluster 1) (Verhaak et al., 2010);
• Mesenchymal subtype (EP=0.85) and PTEN (EP=0.69) are enriched
in the same cluster (cluster 2) (McNamara et al., 2013).
Themost assertive clinical association is the inclusion of younger pa-
tients in the proneural subtype (Verhaak et al., 2010). For the T1-
weighted post contrast MRI, the average age of a patient in cluster 1 is
52.5 years as opposed to 59 years in cluster 2. Similarly, for the T2-
weighted FLAIR MRI, the average age of a patient belonging to cluster
1 is 51.3 years, which is distinctly lower than the average age of
61.1 years in cluster 2. For the bivariatemodality, we note a slight differ-
ence in the average age of a patient in each cluster: 54.16 years for clus-
ter 1 and 57.53 years in cluster 2. For all of the modalities, the classical,
mesenchymal and neural tumor subtypes are enriched in cluster 2
whereas the proneural subtype is highly enriched in cluster 1. The
proneural tumor subtype is associated with a longer overall survival
time and better prognosis than that for the classical tumor subtype
(Lin et al., 2014) and mesenchymal tumor subtype, which has the
worst patient prognosis (Naeini et al., 2013). For all modalities, the
proneural subtype is highly enriched in the cluster with higher mean
and median survival while the classical and mesenchymal subtypesnumbers represent the average difference in cluster-wisemean andmedian survival times
(in months) for each modality obtained using k-means clustering. Numbers in parenthe-
ses represent standard deviation of the differences based on 100 different initializations
of the clustering algorithm.
T1-weighted post
contrast
T2-weighted
FLAIR
Difference Difference
Skew., Kurt., Range, Mode
(Baek et al., 2012)
Mean 0.08 (0) 1.01 (0.55)
Median 0.05 (0) 1.81 (0.04)
5th and 95th percentile
(Song et al., 2013)
Mean 6.85 (0.55) 2.64 (2.30)
Median 6.92 (0.26) 1.38 (1.05)
25th and 75th percentile
(Just, 2011)
Mean 4.94 (≈0) 2.96 (1.03)
Median 5.10 (≈0) 2.36 (0.88)
Fig. 8.Enrichment plots for tumor subtype and genomic covariates for the T1-weightedpost contrastMRI (left) and the T2-weighted FLAIRMRI (right). The color key is providedbelow the
enrichment plots.
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al times.
5. Discussion and future work
We have deﬁned a novel representation of tumor heterogeneity
based on T1-weighted post contrast and T2-weighted FLAIRMRImodal-
ities that is a probability density function estimated from tumor intensi-
ty histograms.Whilemostmethods have used summary statistics of the
intensity histograms to study tumor heterogeneity, we proposed to
study the full THDPs under the Fisher–Rao Riemannian-geometric
framework through our method DEMARCATE. For each patient and
each MRI modality, we apply the DEMARCATE pipeline: (1) extract
pixel intensity values corresponding to the tumor, (2) estimate the
THDP from the intensity histogram using kernel density estimation,
(3) transform the estimated THDP to its SRT representation, and (4)Fig. 9.Graphs (a) and (c) show a two-dimensional plot of theﬁrst two principal component sco
direction of variability. Blue =−2 standard deviations (sd); green =−1 sd; red = mean; cyapply k-means clustering on the space of THDPs to separate the patients
into two groups. This framework allows for intrinsic summarization and
clustering of the patients based on their respective THDPs. We have
shown through multiple analyses that the computed cluster member-
ships are associated with distinct clinical characteristics, molecular
tumor subtypes and driver genemutations. This shows promise for DE-
MARCATE in further radiogenomic studies of GBM. Although applied to
a speciﬁc imaging modality (MRI) in GBM, the proposed technique can
be used for any voxel-level data and is not conﬁned to MRI data alone.
In spite of recent advancements in theﬁeld of radiogenomics, clinical
diagnosis of the affected tissue region is still required to differentiate be-
tweenprimary andmetastatic brain tumors. For large populations of pa-
tients, validation and standardization of the proposed density-based
clustering approach to analyze MRI data in GBM is a demanding chal-
lenge. If validated in a suitably matched large clinical cohort, DEMAR-
CATE can be reliably used for any imaging modality to segregate andres. Cluster 1 is represented in blue and cluster 2 in red; (b) and (d) show theﬁrst principal
an = +1 sd; magenta =+2 sd.
TT
142 A. Saha et al. / NeuroImage: Clinical 12 (2016) 132–143inspect tumor heterogeneity through noninvasive means. Future direc-
tions of study include exploring phenotypic characteristics in each clus-
ter identiﬁed from the two MRI modalities.
Although the current framework for clustering patients with GBM
using their THDPs extracted from 2DMRI modalities is showing promise,
there is clear room for improvement. In particular, one could use the full
3D tumor information to form the THDPs for clustering purposes. This
presents a way to suitably leverage all the intensity information in the
tumor rather than just the information contained in the largest slice. Sec-
ondly, important spatial information is discarded during the construction
of THDPs. We are currently working on extending the THDP representa-
tion to include spatial information in addition to pixel/voxel intensities.
Finally, the versatility of the proposed representation of tumor heteroge-
neity allows for simultaneous analysis of multiple THDPs corresponding
to relevant tumor compartments. This extension would allow for a
more in-depth analysis of intra-tumor heterogeneity.Acknowledgements
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A gradient-based algorithm for computing the Karcher mean on Ψ
(Dryden andMardia, 1998; Kurtek, 2016) is presented below for conve-
nience. This algorithm can be initialized using either one of the THPDs in
the given sample or the extrinsic average.
The k-means algorithm on Ψ minimizes the within-cluster Karcher
variance if we choose the cluster center to be the Karcher mean and the
distance to be the FR distance. Let f1 ,… , fn denote a sample of THDPs,
and ψ1 ,… ,ψn be their respective square root representations. The k-
means clustering algorithm (MacQueen, 1967) onΨ is given as follows.Appendix B
Table B1
The following table contains pooled Karcher variances for the three initialization strate-
gies: (1) hierarchical clusteringwith complete linkage, (2) hierarchical clusteringwith av-
erage linkage, and (3) partitioning around medoids (PAM).MRI modality Hierarchical
(complete)Hierarachical
(average)PAM1-weighted post
contrast2.6663 5.5457 2.44462-weighted FLAIR 5.0315 5.7524 2.3261
ivariate 14.7683 17.4325 9.3037BTable B2
The following table shows the frequency of different tumor subtypes in the dataset. Note
that a GBM tumor may simultaneously belong to two different tumor subtypes.Tumor subtype Classical Mesenchymal Neural Proneuralequency 28 30 13 11FrTable B3
The following table shows the frequency of driver gene alterations in the dataset. The
numbers in parentheses represent percentages.Driver gene
with alterationsDDIT3 EGFR KIT MDM4 PDGFRA PIK3CA PTENequency (%) 6 (9.4) 24 (37.5) 5 (7.8) 4 (6.3) 7 (10.9) 5 (7.8) 5 (9.4)FrTable B4
The acquisition sequences for the T1-weightedpost contrast andT2-weighted FLAIR imag-
ing modalities are given in the following table for the relevant dataset.T1-weighted post contrast T2-weighted FLAIRE: 2.1–20 ms TE: 14–155 ms
R: 4.944–3256.24 ms TR: 400–11,000 ms
ice thickness: 1.4–5 mm Slice thickness: 2.5–5 mm
acing between the slices: 0.7–6.5 mm Spacing between the slices: 2.5–7.5 mm
atrix size: 256 × 256 or 512 × 512 Matrix size: 256 × 256 or 512 × 512
ixel spacing: 0.468–1.016 mm Pixel spacing: 0.429–0.938 mmPAppendix C
In Fig. 9, we plot each THDP using its ﬁrst two principal component
scores, which are found by PCA (Section 3.4.2) of the entire dataset (not
cluter-wise).We do this separately for eachmodality (univariate THDPs
only) and plot the two clusters using different colors; additionally, we
investigate the principal direction of variation. The clusters for eachmo-
dality are well separated along the principal direction of variability
(right side of each panel in Fig. 7).References
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